Clinical Trials Logo

Filter by:
NCT ID: NCT01056809 Terminated - Colorectal Cancer Clinical Trials

Treatment Strategies for Primarily Generalized Colorectal Cancer

PGC
Start date: January 2010
Phase: N/A
Study type: Interventional

For patients with primarily generalized colorectal cancer two treatment strategies are compared to establish which strategy gives best overall survival. The traditional strategy is to first resect the primary colorectal tumour and then treat the metastases with chemotherapy followed if possible by surgery. The alternative strategy is to first treat the metastases with chemotherapy followed if possible by surgery and only resect the primary colorectal tumour if there is hope for cure or if symptoms develop that necessitates treatment.

NCT ID: NCT01039376 Terminated - Clinical trials for Leukaemia, Lymphocytic, Chronic

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

PROLONG
Start date: May 6, 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study was to determine if maintenance therapy with ofatumumab would prolong remission in patients with CLL who have responded to second or third line treatment. This study would also evaluate the safety of ofatumumab maintenance compared to observation (the current standard of care). This study was co-developed with the HOVON and NORDIC CLL group and would be conducted as a collaborative effort with GSK.

NCT ID: NCT01032291 Terminated - Colorectal Cancer Clinical Trials

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.

NCT ID: NCT01018953 Terminated - Carcinoid Syndrome Clinical Trials

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

CAMPANULA
Start date: February 2010
Phase: Phase 2
Study type: Interventional

The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient's overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.

NCT ID: NCT01016951 Terminated - Healthy Clinical Trials

A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease

Start date: December 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled AZD9164 following administration of multiple ascending doses in healthy male and female subjects and COPD patients.

NCT ID: NCT01016795 Terminated - Malignant Lymphoma Clinical Trials

Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma

SCF980266
Start date: January 1999
Phase: Phase 2
Study type: Interventional

Clinical Hypothesis: It is expected that by removing chemotherapy and adding ancestim to the mobilization scheme in most of the subjects sufficient PBPC will be harvested with a minimum of toxicity and side effects.

NCT ID: NCT01006252 Terminated - Melanoma Clinical Trials

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

SUMMIT-1
Start date: December 2009
Phase: Phase 3
Study type: Interventional

The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.

NCT ID: NCT00999518 Terminated - Clinical trials for Cystitis, Interstitial

A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

Start date: January 22, 2010
Phase: Phase 2
Study type: Interventional

In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary urgency. Only one dose was studied, and tanezumab was well tolerated. In this study, the hypothesis being tested is that tanezumab will show efficacy at several doses on reducing pain with sufficient tolerability. Tanezumab's safety will also be assessed at different dose levels

NCT ID: NCT00998764 Terminated - Alzheimer Disease Clinical Trials

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3001(NCT00676143). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.

NCT ID: NCT00996918 Terminated - Alzheimer Disease Clinical Trials

A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.